Bora Biologics and Protect Animal Health Launch Multi-Project Antibody Collaboration

Bora Biologics, a technology-driven contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics, has entered a strategic, long-term, multi-project collaboration with Protect Animal Health, a U.S.-based animal-health company focused on innovative therapeutics.borabiologics

The partnership is designed to advance the development and manufacturing of antibody-based animal-health products, including monoclonal antibodies (mAbs) and bispecific antibodies, for companion and production animals in the United States and international markets.

Terms of Agreement

Under the agreement, Bora Biologics will provide end-to-end development and manufacturing support, leveraging its mammalian and microbial expression platforms, process development capabilities, and GMP manufacturing infrastructure. Protect Animal Health will contribute its portfolio of antibody candidates, disease-area expertise, and commercialization capabilities in the veterinary sector.

While specific targets and indications have not been disclosed, the collaboration underscores the growing role of antibody therapeutics in veterinary medicine, building on recent momentum in canine oncology mAbs, anti-inflammatory antibodies, and production-animal biologics.

Implications for Animal Health Industry

The deal also highlights the expanding CDMO model in animal health, where specialized manufacturers partner with innovator companies to accelerate pipelines without the need for in-house biologics capacity.

Financial terms and project timelines were not disclosed. Both companies indicated that additional program details will be shared as candidates advance through development.